Novo Nordisk shares plunge after CagriSema obesity drug trial disappoints

Novo Nordisk on Friday revealed disappointing results in a late-stage trial for its experimental next-generation obesity drug CagriSema, wiping as much as $125 billion off its market value.

Sign up for Reuters newsletters Reuters Business Reuters Business

Novo Nordisk shares plunge after CagriSema obesity drug trial disappoints

Ex-IMF chief Rato sentenced to 4 years, 9 months in prison over corruption case

Trump aims at Biden's Inflation Reduction Act: EVs, clean energy and manufacturing

Global equity funds faced huge outflows ahead of Fed decision

US equity funds saw biggest net outflows in 15 years ahead of Fed decision

VW and union getting closer to deal, sources say

FedEx's freight spinoff plan to fortify core business, boost industry

Italy fines OpenAI 15 million euros over privacy rules breach

Turmoil at Colombia's Ecopetrol raises profit fears ahead of US investment decision

Global central banks urge caution before Trump arrival

Sponsors are not involved in the creation of newsletters or other Reuters news content. Advertise in this newsletter or on Reuters.com Reuters Business is sent every weekday. Think your friend or colleague should know about us? Forward this newsletter to them. They can also sign up here. Want to stop receiving this email? Unsubscribe here. To manage which newsletters you're signed up for, click here. Terms & Conditions and Privacy Statement

© 2024 Thomson Reuters. All rights reserved. 3 Times Square, New York, NY 10036